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Abstract: After organ transplantation, gamma glo-
bulin and intravenous immunoglobulin enriched with
IgM are most frequently used in septic shock as early
immune-support. If the explanted organ is infected, the
transplantation, as a life-saving operation, can be perfor-
med if there is no systemic inflammation and the patient
receives IgM enriched immunoglobulin prophylaxis du-
ring surgery. The period after transplantation can be di-
vided into three parts from the infection point of view:
the first month after transplantation, the first sixth
months and the following six months. Infections within
the first month are basically related to the surgical pro-
cedure. Because of the immunosuppressive therapy, the
opportunistic and fungal infections are more common
during the first sixth months. After this period, the oc-
currence and the type of infections are similar to that of
the non-transplant population except for pulmonary in-
fections. The latter is two to three times more frequent.
This is explained by the secondary hypogammaglobuli-
naemia (lower blood levels of IgM and IgG) which is
caused by the steroids but most ofmycophenolatemofe-
til by inhibition of the T and B lymphocyte proliferation.
Septic shock develops with a continuing fall of IgM le-
vels. Under these circumstances additional intravenous
immunoglobulin therapy with IgM can be lifesaving.
Besides, immunoglobulin concentrates with IgM may
also be used in the case of viral infections without pro-
phylaxis and/or without etiological therapy such as in
the case of West Nile virus infection. As a result of the
increase in antibiotic resistance, the application of im-
munotherapy, including immunoglobulins may become
the mainstream in the treatment of septic shock.
Key words: immunoglobulin, IgM, septic shock,
transplantation.
INTRODUCTION
The immunoglobulin therapy started more than
100 years ago with the use of anti-diphtheria serum
from horse and continued with the successful treatment
of primary and secondary immunodeficiency with in-
travenous immunoglobulin (IVIG) products. Later on,
this was augmented by the use of gamma globulin in
the treatment of Guillan Barré syndrome, Kawasaki di-
sease, chronic demyelinating polyneuropathy and dif-
ferent autoimmune diseases. Currently, the use of IVIG
is integrating evidence-based practice in this field (1).
The use of immunoglobulin in severe sepsis, septic
shock is controversial (2, 3, 4), but a recent Cochrane
analysis from 2013 highlighted the favorable effects of
early treatment (5) (Table 1).
Monserrat et al. proved that the B lymphocytes re-
duced CD23 and elevated CD80 production in septic
patients, which may result in high mortality rates (6).
Moreover, the altered rate of immunoglobulin produc-
tion also showed effects on outcome in sepsis: IgG1,
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Neutralisation of toxins
• Endotoxin, exotoxin, Gram negative bacterium:
molecular patterns
• Reception of endotoxin by the liver and the spleen
• Decreases the bacterium’s adherence to other organs
Leukocyte stimulation and increased
bactericide effect
• Neutrophil: increased phagocytosis
• Increased opsonization
• Increased oxidative bactericide effect on
T lymphocyte
• Kuppfer cell increased phagocytosis
Inflammatory cytokine effect regulation
• decrease of pro-inflammatory cytokine
• Increase of anti- inflammatory cytokine
Complement effect modulation
• C4, C3 effect reduction through leukocyte
Table 1. Effects of intravenous immunoglobulin
total IgG, IgM and IgAhave an independent protective
role in severe sepsis and septic shock (7, 8).
During the last decade, the number of nosocomial
infections caused by multiresistant pathogens increa-
sed significantly and further increase is expected. The
development of antibiotics can only hardly or not at all
keep up with the change of resistance, thus sooner or
later the need for the wider use of immunoglobulins
may become a reality (9, 10). It is important to note,
that the guidelines in 2013 also recommend IVIG for
the therapy resistant or severe Clostridium difficile in-
fections (11).
In the field of transplantation, immunoglobulins
are also used for the treatment of immunological disea-
ses with infectious or non-infectious causes. One op-
tion for the treatment of non-infectious diseases is the
therapy of antibody-mediated rejections or for exam-
ple desensibilisation (12). The other option is the adju-
vant treatment of transplanted patients, which is usu-
ally performed with the use of gamma globulin or in-
travenous immunoglobulin enriched with IgM. The
early use of immunoglobulins in septic shock in trans-
planted patients is logical because of the immunosup-
pression (Figure 1).
INFECTIONS DURING
TRANSPLANTATION
Immunosuppression of the recipient can clearly
be verified before transplantation based on the major,
minor and laboratory criteria of immunodeficiency
(13). Infections during transplantation occur because
of the immunodeficient state due to the end-stage or-
gan failure and the transitory ceasing of the barrier fun-
ctions protecting the integrity of the body during the
surgical procedure. Kidney failure and its treatment
correlates with the reduced function of specific and
non-specific protecting mechanisms. In case of perito-
neal or hemodialysis the insufficiency of the non-spe-
cific protecting mechanisms may develop. The impair-
ment of the specific protecting components occurs dur-
ing the contact with the dialysis membrane (loss of
complements, leukocyte dysfunction, IgG and IgM re-
duction due to the increased loss of proteins), but the
reduction of the cellular immunity is due to the direct
effects of uremia (14). Acute liver-failure as well as
end-stage cirrhosis also implies immunodeficiency.
The immunological role of the liver as we know is ex-
tremely important: the Kuppfer cells of the liver elimi-
nate endogen bacteria from the portal vein, the liver
synthetizes 90% of the complement cascade and the li-
ver eliminates the extrahepatically opsonized bacteria.
In liver-failure both the production of complements
which take part in the opsonization, and the elimina-
tion of the opsonized organisms are severely impaired.
In 80% of patient suffering from end-stage liver failure
severe infections can be found, and in quarter of these
patients have detectable bacteremia. The bacterial in-
vasion’s primary places of occurrence are the respira-
tory, urinary and peritoneal space.
In case of the intestinal flora-originated bacteremia
(Escherichia coli, Klebsiella) the bacteria get through to
the peritoneal space, where in the presence of ascites
spontaneous bacterial peritonitis (SBP) can develop.
The diagnosis is based on the increased number of leu-
kocytes in the ascites (in ascites > 250 cell/ml) or the di-
rect detection of the pathogen from the ascites (15).
The relationship between end-stage heart and lung
disease and infection is a long known fact. There is we-
aker protection due to impaired circulation and oxyge-
nation, which results in the disorder of the natural, not
specific immunity which provides weaker protection
against aerobic and anaerobic pathogens.
Infection occuring during the operation is caused
by the breakthrough of bacteria through barriers pro-
tecting the body’s integrity. The translocation is also
helped by the transitory changes in the perfusion and
oxygenation during the operation (14). Furthermore,
there is a possibility of the donor organ carrying infec-
tion. When the focus of the infection is localized in the
organ waiting to be removed and there is no systemic
inflammation, hence the focus is inactive, under well-
-defined circumstances the transplantation as a live-sa-
ving operation can be performed. In this case the IgM-
-enriched immunoglobulin prophylactic therapy is rec-
ommended only during the time of the surgical proce-
dure. A typical example is the cholangitis in patients
suffering from ulcerative colitis causing cirrhosis and
sometimes occurring with abscesses, or the primer bili-
ary cirrhosis where in the recipients in the portal triads
fragments of translocated bacteria and IgM can be
identified together (16). Prior to transplantation the
acute infection must be ruled out. In the literature there
are case studies indicating that in certain cases it is pos-
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Figure 1. Immunoglobulin products used with
transplanted patients
sible to go astray from the guidelines. For example in a
patient suffering from acute bacterial infection the
transplantation can be performed, but it can only be do-
ne under the protection of IgM-enriched immunoglob-
ulin. In addition the infection can be completely oblite-
rated until the 5th postoperative day or until when the
combined immunosuppression is being built up (7, 17).
There are Hungarian experiences as well in this field.
We recently treated a 30 year old mother of three chil-
dren, whose antibiotic treatment for a right sided pneu-
monia lasted 3 months after the delivery of the third
child, caused acute liver failure. Liver transplantation
was performed along the specific antibiotic therapy
and IgM-enriched immunoglobulin treatment, which
was successful and the mother is still alive.
INFECTION AFTER
TRANSPLANTATION
The period after solid organ transplantation (SOT)
can be divided into three parts from the infections point
of view: the first month after transplantation, the first
and the second sixth months. The “golden rule” is that
the development of rejection indicates development of
infection and the development of infection indicates de-
velopment of rejection (15, 18). The timescale of the
transplanted patients’ infections offers help in differen-
tial diagnosis and in planning the effective prophylaxis
and empirical atibiotic therapy. It has a particular impor-
tance in the perioperative period, if there are other surgi-
cal procedures performed for other reasons (Figure 2).
The 1
st
month
In case of infections during the first month the
possibility of transition from the donor arises, but the
infections generally correlate to the surgical procedure
as well. The use of complex immunosuppression ther-
apy begins immediately after surgery and requires ti-
me, therefore the early postoperative infections are
mainly unrelated to the immunosuppressed state. The
prevalence and type of infections match the not immu-
nosuppressed patient’s infections associated to surgi-
cal procedures. In this period pneumonia, urinary and
biliary tract infection related to catheter, drain or intra-
venous devices can occur. In case of liver-transplanted
patients, due to the surgical interventions of choledoc-
hotomy, choledochojejunostomy, the ascending type
biliary infections are the most frequent, in cases of kid-
ney-transplanted patients the urinary tract infections,
in heart-transplanted patients mediastinitis or the aorta
suture’s fungal infection, in cases of lung-transplanted
patients the bronchial anastomotic insufficiency or me-
diastinitis can develop (14). During the first weeks af-
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Figure 2. Occurrence of infections in timely order after transplantation
* CMV: cytomegalovirus; HSV: herpes simplex virus; CNS: central nervous system; TBC: tuberculosis; UTI: urinary tract infec-
tions; VZV: varicella zoster virus
ter transplantation acute rejection can occur, of which
treatment consists of usually administration of large
dose steroids or anti-lymphocyte globulin. In this case
the “over” immunosuppression is in favor of the appea-
rance of the more severe opportunistic infections. The
chronic lymph loss in the first few days caused by the
damage of the lymphatic vessels during the operation
could play a distinct role in the development of redu-
ced immunoglobulin levels in the immediate postoper-
ative period. These can cause immunosuppressed state
by themselves and with addition of the drug-induced
immunosuppression. Together they surely cause “over”
immunosuppression, although separately they don’t
(19, 20) (Table 2).
Moreover, steroids but mostly the T and B lympho-
cyte proliferation inhibitor mycophenolate mofetil also
contributes to the reduced IgM and IgG blood levels. So
it is logical that during the treatment of infections based
on surgical complication, polytransfusion or systematic
disease in the early stages of septic shock parallel with
the application of the sepsis guidelines IgM-enriched
immunoglobulin therapy can also be used.
From th 1
st
to the 6
th
months
after transplantation
The period between the first and sixth months af-
ter transplantation is when the nature of the transplan-
ted patients’ infections changes. The immunosuppres-
sion applied during transplantation inhibits the acqui-
red immunity and is heterogenic and its complexity is
given by the possibility of the combinations. We inhi-
bit the antigen recognition with the help of steroids, the
proliferation with the help of mycophenolate mofetil.
The inhibition of the cytokines’ production is the most
commonly used option to prevent rejection and lately it
is often combined with co-stimulation blockade. The
effect of the combined immunosuppression is stron-
gest between the first and sixth months after transplan-
tation, therefore the classic opportunist infections are
to be expected during this period: they develop in
33–68% of liver-transplanted patients, in 54% of lung
transplanted patients, in 47% of kidney transplanted
patients, in 35% pancreas transplanted patients and in
21–30% of heart transplanted patients (Figure 1).
Out of the opportunistic viral infections the mem-
bers of the herpes family have the highest significance,
their main representative is the herpes type B cytome-
galovirus infection (CMV). The CMV infection with a
prolonged epidemic-like occurrence affects 10–50 %
of the transplanted population. Its development de-
pends on the donor’s and the recipient’s serological
status, the characteristics of immunosuppression, the
human leukocyte antigen (HLA) accordance and the
type of the transplanted organ. It can appear as a mild
or moderately severe “flu-like” syndrome, progressive
colitis, hepatitis or gastritis, leukopenia, pneumonia or
disseminated viral disease. Besides the direct effects of
CMV the indirect effects are also very important. The
CMV infection through its effects on the immune sys-
tem raises the chance of opportunistic infections, e.g.
in the presence of CMV infection the number of invasi-
ve fungal infections increases by 5–6–fold (21).
Among the other members of the human herpes
virus family the HHV6 and HHV8 are the most impor-
tant, which can cause for example pneumonia, enceph-
alitis or myelosuppression. Their harmful effect as a
cofactor is mostly set forth through immunomodula-
tion, making the appearance of opportunist pathogens
easier. One clear example for this is the role of Kaposi
sarcoma-associated herpes virus (KSHV-HHV8) in the
development of the transplantation-related late Kaposi
sarcoma (21).
After transplantation in seronegative patients the
varicella-zoster virus (VZV) can cause varicella, in se-
ropositive patients it can cause herpes zoster. To pre-
vent infection there is a blood test before the transplan-
tation and depending on the result vaccination is advi-
sed. In bacterial or fungal superinfections immunoglo-
bulin therapy should be considered (22).
Invasive fungal infections can originate from both
endogen and exogen flora. The infection’s progression
is fast, therefore the initiation of the early empirical
therapy is very important. Besides the adjuvant use of
IgM-enriched immunoglobulins is an important and
common sense part of the therapy. The aspecific clini-
cal picture causes great difficulties in early diagnosis.
The appearance of the non-albicans Candida, Aspergil-
lus species and Fuzariums have become more and mo-
re common, which cause higher than average mortality
among the immunosuppressed.
The incidence of Pneumocystis jiroveci is 3–11%
without prophylactic treatment, it primarily causes pne-
umonia among the transplanted. It develops mainly in
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Table 2. The protein and immunoglobulin content
of ascites after liver-transplantation (laboratory test
results, own material). Depending on the daily loss,
this lack/deficit can cause immunosuppression
Parameter
Value
measured from
ascites (g/L)
Serum normal
value (g/L)
Total protein 44.3 60–85
IgA 0.83 0.7–4.0
IgG 2.84 7.0–16.0
IgM 0.41 0.4–2.3
patients, who belong to the high risk group. The late di-
agnosis and late treatment causes high mortality here as
well, but it can be easily prevented with prophylaxis (sul-
fonamid/ trimetoprim, in case of allergy pentamidin).
During the second period after transplantation (1–6
months) the opportunistic infections from the environ-
ment are also common (Nocardia, Listeria and Legio-
nella infection), and unlike Mycobacterium, they don’t
cause infection through reactivation.
In severe sepsis and septic shock the use of early
IgM-enriched immunoglobulins within the first 1–2 days
is recommended. In patients suffering from severe sep-
sis, septic shock, the delay in the start of Pentaglobin®
raises the mortality by 2.5% in every 24 hours (23, 24).
This raises the mortality of transplanted patients with
an even higher ratio.
Six months after transplantation
5–10% of the SOT patients develop rejection or
chronic graft insufficiency on an immunological basis.
Among these patients the immunosuppressive therapy
is more pronounced and the therapy against rejection is
also more common. It causes deeper, longer immuno-
suppression with all of its consequences, among which
the prolonged presence of opportunistic infections are
important to note. 10% of patients with chronic rejec-
tion suffer from some kind of chronic, progressive in-
fection as well. Aspecific infections, e.g. nocardiosis,
aspergillosis may develop only from a significant envi-
ronment-originated exposition. On the other hand viral
infections are also common (hepatitis C, B virus; cyto-
megalovirus; Epstein-Barr virus; papillomavirus), which
cause damage to the implanted organ and have a role in
the development of tumors. In the period following the
sixth month after transplantation 80% of SOT patients
have good graft function and receive immunosuppres-
sive treatment at the lowest possible dose. In this case
the type of infections and their incidence usually equ-
als to the non-transplanted population, and only differs
in respiratory tract infections. The cause of this is the sec-
ondary hypogammaglobulinemia (IgG: 400–700 mg%),
which is caused by the mycophenolate mofetil (MMF)
blood levels, which inhibit the T and B lymphocyte
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Figure 3. Supposed infections’ diagnostics and treatment after the transplantation of parenchymal organ
*EBV: Epstein-Barr virus; CMV: cytomegalovirus; PCR: polymerase chain reaction
proliferation (25). In these cases theMMF can be chan-
ged to an alternative drug, and monthly IVIG therapy
can be given during the follow-up. Along the humoral
“over” immunosuppression the prevalence of the pul-
monary infections is 2–3–fold of the normal. Obvio-
usly if the same kind of patient arrives to the intensive
care unit in the state of septic shock, the MMF therapy
is to be stopped and a few days of IgM-enriched intrave-
nous immunoglobulin therapy is recommended (26).
Although the course of bacterial infections look
similar to that of in the non-immunosuppressed popu-
lation, the course of certain viral infections can be mo-
re aggressive among the transplanted patients. In pati-
ents without prophylaxis or without definitive therapy
(e.g. West Nile virus infection) the only treatment we
can offer is the IgM-enriched immunoglobulin therapy
as in addition to supportive therapy (27).
From a practical point of view it is important to be
aware of the applied immunoglobulin product’s char-
acteristics: process of production, the method of con-
servation and most importantly, the pathogen specific
antibody content. Regarding the patient, we have to
know the plasma immunoglobulin content, and the an-
swer to the three most important questions of the im-
munoglobulin therapy: when, how much, for how
long. The details of a septic transplanted patient’s im-
munosuppressed state must be known: its nature, its
depth, its severity and for how long it has lasted, emp-
hasizing the disorder of the cellular immunity. During
the performance of microbiological tests we have to
aim for the direct detection of the pathogen with histo-
logical, microbiological or with other antigen tests
(punctions, bronchoalveolar lavage, biopsy). It is ex-
tremely important to start the combined broad spec-
trum antibiotic, antimycotic therapy immediately after
the samples for microbiological tests are collected.
With the use of laboratory tests in reasonable cases
(MMF, steroids) the serum immunoglobulin levels and
the levels of immunosuppressant must be determined
and with its daily monitoring the doses must be redu-
ced. The use of steroid monotherapy is possible if the
graft function can be replaced with supportive therapy
(e.g. in kidney-transplanted patients: hemodialysis). In
case of a graft which stands for a vital organ the MMF
is to be immediately stopped, other immunosuppres-
sion must be reduced to the border of rejection, and
early use of IVIG or IgM-enriched immunoglobulin
therapy must be started to strengthen immunity. Know-
ing the results of the microbiological tests (most likely
the 3-5th day of therapy) antibiotics should be de-esca-
lated, and the immunoglobulin therapy can be stopped
(28, 29). The occurrence of potential side-effects, e.g.
the kidney-failure, aberrant immunothrombosis, he-
molysis, should be checked regularly (30) (Figure 2).
CONCLUSION
The use of intravenous immunoglobulins in pati-
ents undergoing SOT shows a growing tendency wor-
ldwide, and one of the main reasons is to aid the host
response to infection. The general concept of organ sup-
port in the critically ill is valid in transplanted patients
too, but the therapeutic window is smaller. Therefore, in
cases of infections in transplanted, immunodeficient pa-
tients, the cornerstones of the treatment are reducing the
degree of immunosuppression, starting empirical anti-
microbial therapy as soon as possible and the use of
IgM-enriched immunoglobulin therapy, besides the spe-
cific diagnostic and therapeutic interventions.
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Sa`etak
ULOGA IgM-OBOGA]ENIH INTRAVENSKIH
IMUNOGLOBULINA U TRANSPLANTACIJI
Szabó Judit, Smudla Anikó, Fazakas János
Semmelweis University, Department of Transplantation and Surgery, Hungary
Nakon transplantacije organa, gama globulini i
IgM-oboga}eni intravenski imunoglubulini su naj~e{}e
kori{}eni u terapiji septi~kog {oka kao rana imuno podr-
{ka. Ako je izvadjeni organ inficiran, transplantacija, kao
operacija od vitalnog zna~aja,mo`e biti izvedena ukoliko
nema sistemske upale i pacijent primi IgM oboga}ene
imunoglobuline kao profilaksu tokom hirur{kog zahvata.
Period nakon transplatancije organa mo`e biti podeljen
na tri perioda u odnosu na infekciju: prvi mesec nakon
transplantacije, prvih {est meseci nakon transplantacije i
slede}ih {est meseci. Infekcije u prvih mesec dana su u
osnovi povezane sa hirur{kom procedurom. Zbog imu-
no-supresivne terapije, oprtunisti~ke i gljivi~ne infekcije
su ~e{}e tokom prvih {est meseci. Nakon ovog perioda,
u~estalost i vrste infekcija su sli~ne onim kod populacije
koja nije imala transplantaciju, osim plu}nih infekcija,
koje su dva do tri puta ~e{}e. Obja{njenje je sekundarna
hipogamaglobulinemija (ni`i nivo u krvi IgM i IgG anti-
tela) koja je prouzrokovana steriodima, ali naj~e{}e mi-
kofenolat mofetilom usled inhibicije proliferacije T i B
limfocita. Septi~ki {ok razvija se sa kontinuiranim padom
nivoa IgM antitela. Usled ovih okolnosti dodatna intra-
venska imunoglobulinska terapija sa IgM antitelima mo-
`e biti od `ivotne va`nosti. Osim toga, IgM oboga}eni
imunoglobinimogu se koristiti kod virusnih infekcija bez
profilakse i/ili bez etiolo{ke terapije, kao {to je slu~aj kod
infekcija izazvanih virusom Zapadnog Nila. Kako je ak-
tuelan porast rezistencije na antibiotike, primena imuno-
terapije, uklju~uju}i i imunoglobuline, mo`e biti osnova
u le~enju septi~kog {oka.
Klju~ne reci: imunoglobulini, IgM, septi~ki {ok,
transplantacija.
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